Clinical Trial Update: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating QL1706 in combination with chemotherapy for patients with PD-L1-negative non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING